blog

GLP-1 intermediates market analysis: demand drivers, supply chain breakdown, peptide vs small‑molecule intermediates, and sourcing tips for buyers.

Brigatinib manufacturer guide: Takeda (brand), Lonza (CDMO), and 72+ API vendors. Patent expiries: China 2026, US 2035. How to choose a reliable supplier for generic development.

This article summarizes 2025 latest research on ibrutinib’s long-term side effects, covering atrial fibrillation, bleeding, hypertension, infections and joint issues. It compares safety with newer BTK inhibitors and notes real-world treatment discontinuation risks.

Orforglipron vs retatrutide: oral small‑molecule GLP‑1 agonist vs triple‑hormone injectable. Phase 3 weight loss data, dosing schedules, side effects, regulatory status, and API manufacturing differences.

Regulatory differences between API and intermediate manufacturing under ICH Q7, FDA, EMA, and NMPA. GMP boundaries, DMF filing, starting material justification.

Finerenone drug class: third‑generation non‑steroidal MRA. Compare selectivity, potency, half‑life, and safety vs spironolactone/eplerenone. FDA‑approved for CKD+T2D and HF with LVEF ≥40%.

Finerenone mechanism of action: a non‑steroidal mineralocorticoid receptor antagonist with high MR selectivity, balanced cardiorenal distribution, no active metabolites, and lower hyperkalemia risk vs steroidal MRAs.

Clascoterone vs minoxidil: Compare mechanisms, Phase 3 trial data, side effects, and whether they work better together. Evidence-based overview for hair loss.

Finerenone vs spironolactone: head-to-head real-world data shows finerenone has 69% lower mortality, 53% fewer kidney events, and less hyperkalemia. Nonsteroidal MRA with no hormonal side effects.

Clascoterone for hair loss: Phase 3 trials show significant regrowth with minimal systemic absorption. How it works, side effects, and comparison to finasteride.